Compare Ascendis Pharma A/S (ASND) vs GraniteShares 2x Long NVDA Daily ETF (NVDL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs GraniteShares 2x Long NVDA Daily ETF — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while GraniteShares 2x Long NVDA Daily ETF trades at $32. The key difference: Ascendis Pharma A/S is trading nearer its 52-week high, GraniteShares 2x Long NVDA Daily ETF nearer its low. Which is the better fit depends on your goals.
| ASND | NVDL | |
|---|---|---|
Market Cap | $17.74B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $277.18 | $43.02 |
52-Week Low | $163.32 | $21.76 |
Enterprise Value | $18.11B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
NVDL, the GraniteShares 2x Long NVDA Daily ETF, trades at $33.03, up 8.08% with a bullish technical signal. Recent stock splits (1:3 on June 25-26, 2026) reflect volatility management. The ETF has shown strong YTD performance (+12.66% as of June 8, 2026) but remains highly sensitive to NVIDIA's daily moves, evidenced by a 12% single-day drop on June 5, 2026. Technical indicators show bullish moving averages but neutral oscillators, with key resistance at $33.
Outlook: High-growth potential tied to NVIDIA's AI dominance, but leveraged structure amplifies risks. Daily resets can erode value during volatility, as seen in early 2025's 67% decline. Investors must weigh AI-driven upside against compounded losses in downtrends. Key risks include NVIDIA-specific volatility and broader semiconductor cyclicality.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About GraniteShares 2x Long NVDA Daily ETF
NVDL is a leveraged ETF that seeks daily investment results corresponding to 200% (2x) of the daily performance of NVIDIA Corporation (NVDA) stock. It is designed as a tactical trading tool for investors with a strong bullish (long) view on NVDA. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment, as its performance over longer periods may significantly deviate from two times the performance of the NVDA stock.
Read more on NVDL →
